Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
lymphomatoid granulomatosis
MeSH D008230 - lymphomatoid granulomatosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D016393:
B-cell lymphoma
15 Companies
7 Drugs
$
Success rate
D011230:
Precancerous conditions
0 Companies
0 Drugs
Success rate
D008230:
Lymphomatoid granulomatosis
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
62
%
31/50
Phase 2
0
%
0/49
Phase 3
100
%
1/1
Approved:
1
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Merck & Co
Interferon alfa-2b
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use